Skip to content

Study · Measured the body's own peptide · 1990

1 result

Interleukin-2-dependent control of disease development in spontaneously diabetic BB rats.

Zielasek J, Burkart V, Naylor P, Goldstein A, Kiesel U, Kolb H

Immunology1 Feb 1990Cited by 25 (Europe PMC)

PMID2307481 (opens in a new tab)PepBankPUB-02307481

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Natural levels measured1

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

  1. 01AnimalEndogenous levelAnimal study (in vivo)Other

    In diabetes-prone BB rats, serum thymosin alpha‑1 concentrations were higher in subline 1 (low diabetes risk) than in subline 2 (high diabetes risk).

    In plain wordsIn rats, the body's own thymosin alpha‑1 level was higher in the subline with low diabetes risk than in the high-risk subline.

    Outcome
    IncreaseSerum thymosin alpha 1 in two BB rat sublines
    Study

    ratn: not reported in source

    diabetes-prone BB rat sublines
    Comparator
    Subline 2
    Outcome group
    Endogenous peptide levels · Endocrine and hormones

    Measurements

    serum level in subline 1 relative to subline 2
    140 to 200%
    subline 1

    Source sentences

    Summary
    mean concentrations of thymosin alpha 1 and beta 4 were higher in subline 1 (between 140% and 200% of levels in subline 2, P less than 0.01).
    1 context sentence
    Summary · context
    Diabetes development was enhanced in the subline with a low intrinsic diabetes risk and suppressed in the subline with a high diabetes risk.

    This result measures the body's own Thymosin alpha-1. Nobody was given the peptide. It is not evidence about taking it.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 08:55 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.